The rise of sono-immunotherapy in Glioblastoma therapy
Source abstract
Abstract
A bstract GBM represents a paradigmatic challenge in oncology, characterized by a distinctively immunosuppressive tumor microenvironment and the formidable BBB that impedes conventional therapeutic delivery. While immunotherapy has revolutionized cancer treatment, its efficacy in GBM remains limited by the “immune-cold” nature of these tumors. Sono-immunotherapy has emerged as a transformative strategy, leveraging the deep-tissue penetration of FUS to mechanically and thermally modulate the TME. This review provides a comprehensive synthesis of the converging frontiers between acoustic physics, immunology, and advanced biomaterials science. We critically examine how ultrasound-responsive biomaterials—ranging from engineered sonosensitizers and functionalized nanocarriers to genetically modified bacteria—orchestrate potent antitumor immunity. We detail the mechanisms by which these bioactive agents harness ultrasonic energy to induce ICD, breach the BBB/brain-tumor barrier, and repolarize tumor-associated macrophages. Furthermore, we highlight recent innovations in “sono-activatable” engineered living materials, such as bacteria programmed with thermal switches for precise payload release. By integrating materials engineering with immuno-oncology, this review outlines a roadmap for next-generation sono-immunotherapeutic platforms capable of overcoming the systemic and local barriers in GBM treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications · Vagus Nerve Stimulation Research · Cancer, Stress, Anesthesia, and Immune Response
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (90)
Show source-provided references
1. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes10.3390/cancers17010146 ↗
2. Evaluating the impact of performance status in elderly patients with glioblastoma10.1016/j.jocn.2024.111028 ↗
3. CAR T treatment beyond cancer: hope for immunomodulatory therapy of non-cancerous diseases10.1016/j.lfs.2024.122556 ↗
4. Current state of immune checkpoints therapy for glioblastoma
5. Deciphering the link: ferroptosis and its role in glioma
6. Current state of immune checkpoints therapy for glioblastoma
7. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives10.1186/s13045-024-01544-7 ↗
8. CAR-T cell therapy for hematological malignancies: history, status and promise
9. Moving towards personalized treatments of immune-related adverse events10.1038/s41571-020-0352-8 ↗
10. The emergence of cancer sono-immunotherapy
11. Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy10.1136/jitc-2022-006226 ↗
12. Sono-immunotherapy for lung cancer utilizing targeted preactivated neutrophil membrane-coated nanoparticles10.1021/acs.bioconjchem.5c00437 ↗
13. Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma10.1016/j.actbio.2025.05.029 ↗
14. Overview of therapeutic ultrasound applications and safety considerations: 2024 update10.1002/jum.16611 ↗
15. Deciphering the link: ferroptosis and its role in glioma
16. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment10.7150/thno.82005 ↗
17. Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of Neuro-Oncology (EANO) consensus review on current management and future directions10.1093/neuonc/noaa287 ↗
18. Comparison of sodium fluorescein and intraoperative ultrasonography in brain tumor resection10.1016/j.jocn.2022.10.019 ↗
19. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches10.1186/s12951-022-01610-7 ↗
20. Nanotechnology-enabled therapies improve blood-brain barrier challenges in brain tumor10.1080/00914037.2023.2291105 ↗
21. Glioblastoma—A contemporary overview of epidemiology, classification, pathogenesis, diagnosis, and treatment: a review article
22. Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition
23. Immunopathology of glioblastoma
24. Exploring spatially resolved intra-tumoral heterogeneity of glioblastoma and neuronal mechanisms facilitating brain invasion10.1158/1538-7445.AM2024-5666 ↗
25. The tumour microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med
26. Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy10.3389/fimmu.2024.1336476 ↗
27. Sharma · 2025 · 31
28. Endogenous self-peptides guard immune privilege of the central nervous system10.1038/s41586-024-08279-y ↗
29. Sun · 2025
30. Cancer neuroscience and glioma: clinical implications10.1007/s00701-024-06406-2 ↗
31. Rossmeisl · 2025 · vol. 55 · 81
32. Brain regulatory T cells10.1038/s41577-023-00960-z ↗
33. Sphingosine 1-phosphate receptor 1 regulates blood-brain barrier permeability in epileptic mice
34. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma10.1038/s41467-023-35957-8 ↗
35. Blood-tumor barrier in focus-investigation of glioblastoma-induced effects on the blood-brain barrier10.1007/s11060-024-04760-w ↗
36. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas10.1016/j.xcrm.2023.101249 ↗
37. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression10.1007/s00262-021-03130-z ↗
38. Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastoma10.1016/j.jconrel.2024.06.036 ↗
39. Enhanced cavitation dose and reactive oxygen species production in microbubble-mediated sonodynamic therapy for inhibition of Escherichia coli and biofilm10.1016/j.ultsonch.2024.106853 ↗
40. The advance of ultrasound-enabled diagnostics and therapeutics10.1016/j.jconrel.2024.08.039 ↗
41. Novel histopathological biomarkers in prostate cancer: implications and perspectives10.3390/biomedicines11061552 ↗
42. Mechanical HIFU and immune checkpoint inhibition: toward clinical implementation
43. T-lymphocytes from focused ultrasound ablation subsequently mediate cellular antitumor immunity after adoptive cell transfer immunotherapy10.3389/fimmu.2023.1155229 ↗
44. Large-volume focused-ultrasound mild hyperthermia for improving blood-brain tumor barrier permeability application10.3390/pharmaceutics14102012 ↗
45. Enabling chemo-immunotherapy with HIFU in canine cancer patients10.1007/s10439-023-03194-1 ↗
46. Low-intensity pulsed ultrasound reduces lymphedema by regulating macrophage polarization and enhancing microcirculation
47. Exploration of ultrasound‐sensitive biomaterials in cancer theranostics
48. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound10.1080/02656736.2021.1905189 ↗
49. UTMD inhibits pancreatic cancer growth and metastasis by inducing macrophage polarization and vessel normalization10.1016/j.biopha.2023.114322 ↗
50. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity10.1038/s41586-019-1485-8 ↗
51. Piezo1 channel activation in response to mechanobiological acoustic radiation force in osteoblastic cells10.1038/s41413-020-00124-y ↗
52. The mechanotransducer Piezo1 coordinates metabolism and inflammation to promote skin growth10.1038/s41467-025-62270-3 ↗
53. PIEZO1 promotes psoriasis-like skin inflammation in mice via NF-κB/IL-17 signaling pathway activation10.1186/s10020-025-01279-2 ↗
54. Mechanical sensing protein PIEZO1 controls osteoarthritis via glycolysis mediated mesenchymal stem cells-Th17 cells crosstalk10.1038/s41419-025-07577-1 ↗
55. Manganese-doping titanium disulfide cascade nanobioreactors for sequential gas-sonodynamic strategy with immune checkpoint blockade therapy of cancer
56. A T-Cell inspired sonoporation system enhances low-dose X-Ray-Mediated pyroptosis and radioimmunotherapy efficacy by restoring Gasdermin-E expression
57. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity10.1136/jitc-2021-003717 ↗
58. Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer10.1016/j.jconrel.2024.01.034 ↗
59. Ultrasound‐activated precise sono‐immunotherapy for breast cancer with reduced pulmonary fibrosis
60. Polyphthalocyanine-based nanostructure for sono-immunotherapy by reprogramming the tumor microenvironment and blocking immune checkpoint
61. Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles10.1038/s41467-022-31551-6 ↗
62. The heterogeneity and function of stromal cells in the tumor microenvironment
63. Sono‐driven STING activation using semiconducting polymeric nanoagonists for precision sono‐immunotherapy of head and neck squamous cell carcinoma10.1002/adma.202300854 ↗
64. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment10.1186/s40824-023-00350-5 ↗
65. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles10.1038/s41565-022-01134-z ↗
66. Spatially targeted brain cancer immunotherapy with closed-loop controlled focused ultrasound and immune checkpoint blockade10.1126/sciadv.add2288 ↗
67. Ultrasound-mediated remotely controlled nanovaccine delivery for tumor vaccination and individualized cancer immunotherapy10.1021/acs.nanolett.0c03646 ↗
68. Ultrasound improved immune adjuvant delivery to induce DC maturation and T cell activation10.1016/j.jconrel.2022.06.054 ↗
69. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy10.1038/s41565-020-00781-4 ↗
70. Ultrasound-mediated immune regulation in tumor immunotherapy
71. Pyroptosis induction with Nanosonosensitizer-Augmented sonodynamic therapy combined with PD-L1 blockade boosts efficacy against liver cancer
72. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice10.1038/s41467-019-09760-3 ↗
73. MnS nanocapsule mediates mitochondrial membrane permeability transition for tumor ion-interference therapy10.1021/acsnano.3c03670 ↗
74. Engineering layered double hydroxide-based sonocatalysts for enhanced sonodynamic-immunotherapy10.1016/j.nantod.2023.101782 ↗
75. Bioactive layered double hydroxides for synergistic Sonodynamic/Cuproptosis anticancer therapy with elicitation of the immune response10.1021/acsnano.3c11818 ↗
76. Titanium sulfide nanosheets serve as Cascade bioreactors for H2 S-Mediated programmed gas-sonodynamic cancer therapy
77. Immunogenic PANoptosis‐Initiated cancer sono‐immune reediting nanotherapy by iteratively boosting cancer immunity cycle
78. Bacterial outer membrane vesicle-modified metal–organic frameworks for sonodynamic therapy–immunotherapy of breast cancer10.1039/D3NJ03511E ↗
79. Biomimetic piezoelectric nanomaterial-modified oral microrobots for targeted catalytic and immunotherapy of colorectal cancer10.1126/sciadv.adm9561 ↗
80. Immunosonodynamic therapy designed with activatable sonosensitizer and immune stimulant imiquimod10.1021/acsnano.2c03395 ↗
81. Oxygen-deficient molybdenum oxide nanosensitizers for ultrasound-enhanced cancer metalloimmunotherapy
82. Amplifying oxidation stress and T-cell activation by bioactive layered double hydroxide sonosensitizers for enhanced cancer immunotherapy10.1016/j.mattod.2023.06.023 ↗
83. Multifunctional sonosensitizers in sonodynamic cancer therapy10.1039/C9CS00648F ↗
84. Engineered living materials for advanced diseases therapy
85. Bioengineering of bacteria for cancer immunotherapy10.1038/s41467-023-39224-8 ↗
86. Ultrasound-controllable engineered bacteria for cancer immunotherapy10.1038/s41467-022-29065-2 ↗
87. Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy10.1038/s41467-022-31932-x ↗
88. Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria10.1016/j.chempr.2024.01.030 ↗
89. Oncolytic mineralized bacteria as potent locally administered immunotherapeutics10.1038/s41551-024-01191-w ↗
90. How environmental factors affect the structural properties and biofunctions of keratin: a molecular dynamics study